In the present study, we identify two convergent AS regulatory pathways (ZRANB2 and SYF2 splicing factors converging on ECT2 splicing) that control resistance to Doxo in breast cancer, specifically in ER+ERBB2- tumors (the main subtype of breast cancer). This evidence concerns the gene SYF2 and breast carcinoma.